Key Takeaways MRK will report Q4 results on Feb. 3, with investors watching the performance of key non-oncology drugs.MRK is leaning on Capvaxive and Winrevair after strong launches, with $480M and $976M sales in 9M 2025.Animal Health growth and early Enflonsia sales are likely to support MRK's top-line growth beyond oncology.As Merck (MRK) is gearing up to report its fourth-quarter and full-year 2025 results on Feb. 3, investors' focus is likely to be on the sales performance of its blockbuster cancer drug ...